Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicaid Rebates For Part D Duals Would Jeopardize Program, Experts Say

Executive Summary

Some Medicare Part D experts are warning of the unintended consequences that could result from applying Medicaid drug pricing policy to low-income seniors enrolled in Medicare Part D drug plans

You may also be interested in...



House Health Reform Bill Increases Drug Rebates, Drops Part D Donut Hole

The House health care reform bill asks pharmaceutical manufacturers to pay their share of the cost of expanding health care coverage by paying higher rebates on more drugs

House Health Reform Bill Increases Drug Rebates, Drops Part D Donut Hole

The House health care reform bill asks pharmaceutical manufacturers to pay their share of the cost of expanding health care coverage by paying higher rebates on more drugs

Pharma Cost-Saving Options Take Backseat In Senate Reform Roundtable

Proposals to pay for an expansion of health care coverage that would directly affect pharmaceuticals took a backseat to tax-related options during the Senate Finance Committee's May 12 roundtable discussion on financing health care reform

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS050370

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel